Q4 EPS Estimate for Journey Medical Decreased by Analyst

Key Points

• Roth Capital has lowered its earnings estimate for Journey Medical's Q4 2025 to $0.02 per share, down from $0.03, while the full-year consensus estimate is ($1.02) per share.
• Journey Medical reported Q2 earnings of ($0.16) per share, missing estimates by ($0.09), despite revenues of $15.01 million exceeding expectations.
• Recent analyst ratings include a maintained "buy" from Lake Street Capital with a price target of $13.00, while Wall Street Zen downgraded their rating from "buy" to "hold".

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Equities researchers at Roth Capital lowered their Q4 2025 earnings estimates for shares of Journey Medical in a report issued on Tuesday, August 12th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings per share of $0.02 for the quarter, down from their previous estimate of $0.03. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical's FY2026 earnings at $2.00 EPS, FY2027 earnings at $3.00 EPS, FY2028 earnings at $4.66 EPS and FY2029 earnings at $5.24 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.09). The business had revenue of $15.01 million for the quarter, compared to the consensus estimate of $14.93 million. Journey Medical had a negative return on equity of 48.69% and a negative net margin of 15.49%.

A number of other research firms have also weighed in on DERM. Wall Street Zen lowered shares of Journey Medical from a "buy" rating to a "hold" rating in a research report on Sunday, July 6th. Zacks Research cut shares of Journey Medical from a "hold" rating to a "strong sell" rating in a research report on Friday. Lake Street Capital upped their target price on Journey Medical from $9.00 to $13.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. Finally, Alliance Global Partners reiterated a "buy" rating on shares of Journey Medical in a report on Thursday, May 15th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.83.

Journey Medical Stock Up 0.5%

Shares of DERM stock traded up $0.0350 during trading hours on Thursday, reaching $7.0350. The company had a trading volume of 42,355 shares, compared to its average volume of 109,497. The company has a market cap of $163.89 million, a price-to-earnings ratio of -18.53 and a beta of 0.80. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.27 and a quick ratio of 0.95. Journey Medical has a 12 month low of $3.54 and a 12 month high of $8.90. The business has a fifty day simple moving average of $7.15 and a 200-day simple moving average of $6.55.

Institutional Trading of Journey Medical

Several hedge funds have recently made changes to their positions in the company. Police & Firemen s Retirement System of New Jersey bought a new position in Journey Medical during the second quarter worth about $29,000. Bank of America Corp DE lifted its position in Journey Medical by 4,707.0% during the second quarter. Bank of America Corp DE now owns 4,134 shares of the company's stock valued at $30,000 after purchasing an additional 4,048 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Journey Medical in the second quarter worth $36,000. JPMorgan Chase & Co. bought a new position in shares of Journey Medical during the 2nd quarter valued at about $41,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Journey Medical in the second quarter worth approximately $48,000. 7.25% of the stock is currently owned by institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.